Francisco Jimenez Carcamo, MD
Cardiovascular Disease · South Miami, FLNPI 1295787927
Payments from drug & device makers
Across 527 payments — averaging $580.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$73K
- Actelion Pharmaceuticals US, Inc.$53K
- Boehringer Ingelheim$40K
- United Therapeutics Corporation$35K
- Akcea Therapeutics, Inc.$25K
- Pfizer$20K
- plus $59K from 29 others
What the payments were for
- Consulting fees$34,77312%
- Speaking & faculty fees$239,28182%
- Travel & lodging$6,3692%
- Food & beverage$12,4394%
- Education$4540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 83 | $72,958 |
| Actelion Pharmaceuticals US, Inc. | 81 | $52,800 |
| Boehringer Ingelheim | 25 | $39,870 |
| United Therapeutics Corporation | 74 | $35,265 |
| Akcea Therapeutics, Inc. | 33 | $25,485 |
| Pfizer | 40 | $20,355 |
| Esperion Therapeutics, Inc. | 11 | $15,050 |
| AstraZeneca | 22 | $14,494 |
| Merck | 12 | $9,359 |
| Lilly USA, LLC | 9 | $7,087 |
| Kiniksa Pharmaceuticals International, PLC | 10 | $3,684 |
| ZOLL Circulation Inc | 4 | $3,678 |
| Abbott | 16 | $2,679 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $1,129 |
| E.r. Squibb & Sons, L.L.C. | 19 | $395 |
| Johnson & Johnson | 26 | $231 |
| Boston Scientific | 5 | $188 |
| Medtronic | 6 | $158 |
| Novartis | 7 | $119 |
| Lexicon Pharmaceuticals, Inc. | 6 | $103 |
| Alnylam Pharmaceuticals Inc. | 3 | $92 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $86 |
| Gilead | 5 | $80 |
| Amgen | 4 | $75 |
| Biotronik Inc. | 1 | $72 |
| GE HealthCare | 2 | $57 |
| Impulse Dynamics (USA) Inc. | 2 | $52 |
| Astellas Pharma US Inc | 3 | $50 |
| Amarin Pharma, Inc. | 2 | $38 |
| Kestra Medical Technology Services, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sandoz | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$60,053
- JARDIANCE$42,684
- UPTRAVI$41,225
- OPSUMIT$35,605
- TEGSEDI$25,282
- ORENITRAM$20,652
- VYNDAQEL$19,808
- NEXLIZET$15,014
- NEXLETOL$15,014
- FARXIGA$14,406
- VERQUVO$12,200
- Kerendia$11,762
- TYVASO$4,476
- TherOx DS2 Console$3,600
- Catheter$3,600
- Downstream Cartridge$3,600
- ARCALYST$3,518
- Mitra Clip system$2,000
- REMODULIN$1,627
- MitraClip$291
How this compares
$305,794 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 211 | $2,662,176 |
| AdempasRiociguat | 80 | $1,135,416 |
| Orenitram ErTreprostinil Diolamine | 85 | $1,035,308 |
| VyndamaxTafamidis | 30 | $873,821 |
| UptraviSelexipag | 29 | $700,337 |
| VyndaqelTafamidis Meglumine | 29 | $631,715 |
| EntrestoSacubitril/Valsartan | 541 | $604,919 |
| JardianceEmpagliflozin | 392 | $429,160 |
| EliquisApixaban | 301 | $359,749 |
| WinrevairSotatercept-Csrk | 17 | $314,076 |
| Ambrisentan | 24 | $155,366 |
| XareltoRivaroxaban | 109 | $115,058 |
| FarxigaDapagliflozin Propanediol | 99 | $98,317 |
| Repatha SureclickEvolocumab | 72 | $85,462 |
| Tadalafil | 44 | $54,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $52,800 | $3,362,513240 claims |
| PfizerVyndamax, Vyndaqel, Eliquis | $20,355 | $1,865,285360 claims |
| BayerAdempas, Kerendia | $72,958 | $1,156,474108 claims |
| NovartisEntresto | $119 | $604,919541 claims |
| Boehringer IngelheimJardiance | $39,870 | $429,160392 claims |
| MerckWinrevair, Verquvo | $9,359 | $338,85538 claims |
| Johnson & JohnsonXarelto | $231 | $115,058109 claims |
| AstraZenecaFarxiga | $14,494 | $98,31799 claims |
| Sanofi-aventis U.S. LLCMultaq | $17 | $40,07926 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $15 | $18,40827 claims |
| AmgenCorlanor | $75 | $10,47418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in South Miami
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
- Duccio BaldariWellington$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.